Compare GNW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNW | IDYA |
|---|---|---|
| Founded | 1871 | 2015 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.9B |
| IPO Year | 2004 | 2019 |
| Metric | GNW | IDYA |
|---|---|---|
| Price | $8.75 | $32.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $10.00 | ★ $50.15 |
| AVG Volume (30 Days) | ★ 3.2M | 762.3K |
| Earning Date | 05-02-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 325.00 | 61.90 |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $7,295,000,000.00 | $218,710,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $97.58 |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $5.99 | $13.45 |
| 52 Week High | $9.28 | $39.28 |
| Indicator | GNW | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 48.21 |
| Support Level | $8.84 | $29.47 |
| Resistance Level | $9.08 | $33.63 |
| Average True Range (ATR) | 0.23 | 1.65 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 56.32 | 62.44 |
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.